One of the best Conferences we have viewed to date, and being on replay it can be viewed at your leisure and/or paused – for when your broker calls with that hot new Psychedelic secondary offering.
On September 22nd, 2021, Maxim Group LLC and M-Vest hosted the Advances in Mental Health Virtual Conference. Rick Doblin, PhD, founder and executive director of the Multidisciplinary Association for Psychedelic Studies, provided a keynote address and participated in a live Q&A.
The event also consisted of virtual panels with executive management from approximately 20 companies in the mental health sector, moderated by Maxim Group Research Analysts.
Must be an exclusive member to view – free registration
PRESENTERS:
Achieve Life Sciences (ACHV)
Adial Pharmaceuticals (ADIL) (not psychedelic’s)
Atai Life Sciences (ATAI)
Awakn Life Sciences (AWKNF)
COMPASS Pathways (CMPS)
Enveric Biosciences (ENVB)
Field Trip Health (FTRP)
Lobe Sciences (GTSIF)
Mind Cure Health (MCURF)
Mind Medicine (MindMed) (MNMD)
Mindset Pharma (MSSTF)
Mydecine Innovations Group (MYCOF)
Protagenic Therapeutics (PTIX) (not psychedelic’s)
PsyBio Therapeutics (PSYBF)
Seelos Therapeutics (SEEL)
Small Pharma (DMTTF)
Psychedelic Investor Guide – Coming Next Week
PANELS
Addiction: Fighting the pandemic within the pandemic
Next Gen Psychedelics: Novel Chemical Entities
Clinics and Commercialization
The Second Generation- Beyond Psilocybin and MDMA
Depression: Spravato opened the door, what comes next?
Delivery, Manufacturing, & Technology
Keynote and Q&A with Rick Doblin, PhD
Addiction: Fighting the pandemic within the pandemic
Dr. Jason McCarthy, Senior Managing Director of Equity Research at Maxim Group, sits down with John Bencich, Chief Executive Officer of Achieve Life Sciences (ACHV), William Stilley, Chief Executive Officer of Adial Pharmaceuticals (ADIL), Celia Morgan, PhD., Head of Ketamine Assisted Psychotherapy for Addiction of Awakn Life Sciences (AWKNF), Rakesh Jetly FRCPC, M.D., Chief Medical Officer of Mydecine Innovations Group (MYCOF), Robert Stein, MD, PhD., Chief Medical Officer of Protagenic Therapeutics (PTIX)
Achieve Life Sciences (ACHV)
Adial Pharmaceuticals (ADIL)
Awakn Life Sciences (AWKNF)
Mydecine Innovations Group (MYCOF)
Protagenic Therapeutics (PTIX)
Next Gen Psychedelics: Novel Chemical Entities
Dr. Jason McCarthy, Senior Managing Director of Equity Research at Maxim Group, sits down with Dr. Shaun McNulty, Chief Scientific Officer of Awakn Life Sciences (AWKNF), Nathan Bryson, PhD, Chief Scientific Officer of Field Trip Health (FTRP), James Lanthier, Chief Executive Officer of Mindset Pharma (MSSTF), Joseph Tucker, PhD, of Enveric Biosciences (ENVB), Rob Roscow, Chief Scientific Officer of Mydecine Innovations Group (MYCOF)
Awakn Life Sciences (AWKNF)
Field Trip Health (FTRP)
Mindset Pharma (MSSTF)
Enveric Biosciences (ENVB)
Mydecine Innovations Group (MYCOF)
Clinics and Commercialization
Dr. Jason McCarthy, Senior Managing Director of Equity Research at Maxim Group, sits down with Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences (AWKNF), Joseph del Moral, Chief Executive Officer of Field Trip Health (FTRP), Marco Mohwinckel, Chief Commercial Officer of COMPASS Pathways (CMPS), Robert Barrow, Chief Executive Officer of Mind Medicine (MindMed) (MNMD)
Awakn Life Sciences (AWKNF)
Field Trip Health (FTRP)
COMPASS Pathways (CMPS)
Mind Medicine (MindMed) (MNMD)
The Second Generation- Beyond Psilocybin and MDMA
Dr. Jason McCarthy, Senior Managing Director of Equity Research at Maxim Group, sits down with Robert Barrow, Chief Executive Officer of Mind Medicine (MindMed), (MNMD), Danny Talati, Director, Business Development of Atai Life Sciences (ATAI), Kelsey Ramsden, Chief Executive Officer of Mind Cure Health (MCURF), Carol Routledge, PhD., CMO & CSO of Small Pharma (DMTTF)
Mind Medicine (MindMed)
Atai Life Sciences (ATAI)
Mind Cure Health (MCURF)
Small Pharma (DMTTF)
Depression: Spravato opened the door, what comes next?
Dr. Jason McCarthy, Senior Managing Director of Equity Research at Maxim Group, sits down with Guy Goodwin MD, Chief Medical Officer of COMPASS Pathways (CMPS), Robert Stein, MD, PhD., Chief Medical Offic of Protagenic Therapeutics (PTIX), Raj Mehra, PhD., Chief Executive Officer of Seelos Therapeutics (SEEL), Peter Rands, Chief Executive Officer of Small Pharma (TSXV: DMT, OTC: DMTTF)
COMPASS Pathways (CMPS)
Protagenic Therapeutics (PTIX)
Seelos Therapeutics (SEEL)
Small Pharma (DMTTF)
Delivery, Manufacturing, & Technology
Dr. Jason McCarthy, Senior Managing Director of Equity Research at Maxim Group, sits down with Josh Bartch, Chief Executive Officer of Mydecine Innovations Group (MYCOF), Evan Levine, Chief Executive Officer of PsyBio Therapeutics (PSYBF), Philip Young, Chief Executive Officer of Lobe Sciences (GTSIF), Kelsey Ramsden, Chief Executive Officer of Mind Cure Health (MCURF), Fabio Chianelli, Chief Executive Officer of PharmaTher Holdings (PHRRF)
Mydecine Innovations Group (MYCOF)
PsyBio Therapeutics (PSYBF)
Mind Cure Health (MCURF)
Lobe Sciences (GTSIF)
Keynote and Q&A with Rick Doblin, PhD
Presentation and Q&A with Rick Doblin, PhD, founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS)
DISCLAIMER
The views expressed in these webinars are those of the panelists and do not reflect the views of Maxim Group LLC, M Vest LLC, any of their affiliates or parents, or any other entities (collectively, “Maxim”). Maxim makes no representations about the accuracy or suitability of any information presented in the webinars or any related materials. MAXIM DISCLAIMS ALL WARRANTIES AND CONDITIONS EXPRESS, IMPLIED, STATUTORY OR OTHERWISE REGARDING THE CONTENTS OF THESE MATERIALS, INCLUDING WITHOUT LIMITATION ALL WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY, AND FITNESS FOR A PARTICLAR PURPOSE. Maxim is not liable and disclaims all liability for any claims, losses or damages of any kind arising out of the information presented in this webinar or any use of that information. The webinar is presented for information purposes only and is not intended to provide, and should not be relied on for, tax, legal or accounting advice. You should consult your own advisors with respect to tax, legal or accounting advice. Maxim is not providing investment advice and is not recommending the purchase or sale of any security. Maxim may have a preexisting relationship with certain presenters in this conference, including but not limited to (i) an investment banking relationship in which Maxim received compensation from the presenter (or an entity affiliated with the presenter), (ii) a service relationship in which Maxim retained and compensated the presenter (or entity affiliated with the presenter) for its services, or (iii) a digital marketing advisory relationship in which Maxim received compensation from the presenter (or an entity affiliated with the presenter) for provision of marketing services, including hosting services in connection with this webinar. Presenters are not compensated for their participation in this webinar.
